FdaApplication
NDA 214324
Identifiers
- fda_app_no: NDA214324
Properties
| Property | Value |
|---|---|
| applicant_name | UNITED THERAPEUTICS CORP |
| application_type | NDA |
| approval_date | 2022-05-23 |
Revenue by product
TYVASO DPI
| Period | Revenue |
|---|---|
| Q2 2026 | $326.6M |
| Q1 2026 | $330.3M |
| Q4 2025 | $338.6M |
| Q3 2025 | $336.2M |
| Q2 2025 | $315.2M |
| Q1 2025 | $302.5M |
| Q4 2024 | $273.2M |
| Q3 2024 | $274.6M |
| Q2 2024 | $258.3M |
| Q1 2024 | $227.5M |
| Q4 2023 | $213.7M |
| Q3 2023 | $205.1M |
| Q2 2023 | $193.6M |
| Q1 2023 | $118.7M |
| Q4 2022 | $92.2M |
| Q3 2022 | $63.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TYVASO DPI | TREPROSTINIL | 0.032MG/INH | POWDER;INHALATION |
| TYVASO DPI | TREPROSTINIL | 0.048MG/INH | POWDER;INHALATION |
| TYVASO DPI | TREPROSTINIL | 0.016MG/INH | POWDER;INHALATION |
| TYVASO DPI | TREPROSTINIL | 0.064MG/INH | POWDER;INHALATION |
| TYVASO DPI | TREPROSTINIL | 0.08MG/INH | POWDER;INHALATION |
5 products